^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor) +
    everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Clin Cancer Res
    Title:

    Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer

    Excerpt:
    Clinical targeted sequencing of a tumor biopsy from the original resection revealed BRAFV600E and PIK3CAH1047R mutations.  Because the patient experienced minimal side effects with dabrafenib/trametinib, triple therapy with dabrafenib/trametinib/everolimus was initiated. CT evaluation showed dramatic tumor shrinkage, with increased patency of the airway.
    DOI:
    10.1158/1078-0432.CCR-16-2154-T